These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32774663)

  • 1. Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.
    Maoz-Segal R; Levy T; Haj-Yahia S; Offengenden I; Iancovich-Kidon M; Agmon-Levin N
    World Allergy Organ J; 2020 Aug; 13(8):100448. PubMed ID: 32774663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels.
    Maoz-Segal R; Levenberg G; Levy T; Haj-Yahia S; Shavit R; Machnes-Maayan D; Lifshitz-Tunitsky Y; Niznik S; Offengenden I; Iancovich-Kidon M; Agmon-Levin N
    World Allergy Organ J; 2024 May; 17(5):100905. PubMed ID: 38742157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
    Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
    World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
    Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
    Front Immunol; 2021; 12():635069. PubMed ID: 33737936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
    Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab.
    Maronese CA; Ferrucci SM; Moltrasio C; Lorini M; Carbonelli V; Asero R; Marzano AV; Cugno M
    J Clin Med; 2023 Jan; 12(1):. PubMed ID: 36615181
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 15. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 19. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
    Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
    Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).
    Jang JH; Yang EM; Lee Y; Ye YM; Moon J; Ryu MS; Park HS
    World Allergy Organ J; 2022 Feb; 15(2):100629. PubMed ID: 35280503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.